CPC A61F 7/12 (2013.01) [A61B 6/037 (2013.01); A61F 7/007 (2013.01); A61M 21/02 (2013.01); A61N 1/0456 (2013.01); A61N 1/0484 (2013.01); A61N 1/0526 (2013.01); A61N 1/36021 (2013.01); A61N 1/36025 (2013.01); A61N 1/36028 (2013.01); A61N 1/36031 (2017.08); A61N 1/36034 (2017.08); H04R 1/1016 (2013.01); H04R 1/1091 (2013.01); A61F 2007/0005 (2013.01); A61F 2007/0075 (2013.01); A61F 2007/0093 (2013.01); A61F 2007/126 (2013.01); A61M 2021/0027 (2013.01); A61M 2021/0072 (2013.01); A61M 2021/0077 (2013.01); A61M 2205/054 (2013.01); A61M 2210/0662 (2013.01); A61N 1/327 (2013.01); H04R 1/10 (2013.01); H04R 2460/13 (2013.01)] | 20 Claims |
1. A vestibular neurostimulation device, comprising:
first and second electrodes;
first and second thermoelectric devices thermally coupled, respectively, to first and second earpieces configured to be insertable into respective ear canals of a patient; and
a controller comprising a waveform generator that is configured to deliver a modulated electric signal to the patient through galvanic vestibular stimulation (GVS) using the first and second electrodes and to deliver a time varying thermal waveform to the patient through caloric vestibular stimulation (CVS) using the first and second earpieces simultaneous with the delivery of the modulated electrical signal through GVS,
wherein the CVS and/or GVS is configured to increase a passage of insulin-like growth factor 1 (IGF-1) through a blood-brain-barrier.
|